Abstract
We sought to assess the association between common antihypertensive drugs and the risk of incident cancer in treated hypertensive patients. Using the Korean National Health Insurance Service database, the risk of cancer incidence was analyzed in patients with hypertension who were initially free of cancer and used the following antihypertensive drug classes: Angiotensin-converting enzyme inhibitors (ACEIs); angiotensin receptor blockers (ARBs); beta blockers (BBs); calcium channel blockers (CCBs); and diuretics. During a median follow-up of 8.6 years, there were 4513 (6.4%) overall cancer incidences from an initial 70,549 individuals taking antihypertensive drugs. ARB use was associated with a decreased risk for overall cancer in a crude model (hazard ratio (HR): 0.744, 95% confidence interval (CI): 0.696–0.794) and a fully adjusted model (HR: 0.833, 95% CI: 0.775–0.896) compared with individuals not taking ARBs. Other antihypertensive drugs, including ACEIs, CCBs, BBs, and diuretics, did not show significant associations with incident cancer overall. The long-term use of ARBs was significantly associated with a reduced risk of incident cancer over time. The users of common antihypertensive medications were not associated with an increased risk of cancer overall compared to users of other classes of antihypertensive drugs. ARB use was independently associated with a decreased risk of cancer overall compared to other antihypertensive drugs.
Highlights
Treatment for hypertension has been shown to decrease cardiovascular morbidity and mortality [1,2]
angiotensin receptor blockers (ARBs) use was associated with a decreased risk for overall cancer compared with ARB non-users in a crude model (HR: 0.744, 95% confidence interval (CI) 0.696–0.794), an age- and sex-adjusted model (HR: 0.822, 95% CI: 0.769–0.878), and a fully adjusted model (HR: 0.833, 95% CI: 0.775–0.896)
Among five common antihypertensive drugs (ACEI, beta blockers (BBs), calcium channel blockers (CCBs), ARB, and diuretics), ARB use was independently associated with a decreased risk of cancer overall compared to other antihypertensive drugs, and the risk of incident cancer overall was decreased further with a longer duration of ARB use
Summary
Treatment for hypertension has been shown to decrease cardiovascular morbidity and mortality [1,2]. A variable proportion of patients with hypertension are treated with antihypertensive drugs, including ACEIs, ARBs, BBs, CCBs, and diuretics in different countries [3]. Given that antihypertensive drugs are used long term, without discontinuation, and that cancer is the second leading cause of mortality worldwide [4], it is reasonable to investigate incident cancer as a possible side effect when selecting the primary agents for hypertension treatment [5]. ARBs, which represent the most recently developed antihypertensive drug class, were introduced in the 1990s [15], and the long-term use of ARBs in relation to incident cancer still requires further investigation.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
